Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1996 2
1997 1
1998 1
1999 1
2003 2
2004 3
2005 1
2006 2
2007 5
2008 4
2009 2
2010 8
2011 6
2012 3
2013 3
2014 4
2015 2
2016 3
2017 1
2018 2
2019 3
2020 6
2021 3
2022 2
2023 1
2024 1
2025 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

69 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for ruttinger d
Search for Ruettinger D instead (2 results)
Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy.
Ries CH, Cannarile MA, Hoves S, Benz J, Wartha K, Runza V, Rey-Giraud F, Pradel LP, Feuerhake F, Klaman I, Jones T, Jucknischke U, Scheiblich S, Kaluza K, Gorr IH, Walz A, Abiraj K, Cassier PA, Sica A, Gomez-Roca C, de Visser KE, Italiano A, Le Tourneau C, Delord JP, Levitsky H, Blay JY, Rüttinger D. Ries CH, et al. Among authors: ruttinger d. Cancer Cell. 2014 Jun 16;25(6):846-59. doi: 10.1016/j.ccr.2014.05.016. Epub 2014 Jun 2. Cancer Cell. 2014. PMID: 24898549 Free article.
Sevabertinib in Advanced HER2-Mutant Non-Small-Cell Lung Cancer.
Le X, Kim TM, Loong HH, Prelaj A, Goh BC, Li L, Fang Y, Lu S, Dong X, Wu L, Shinno Y, Daniele G, Yang TY, Kim HR, Ruiter G, Zhao J, Novello S, Miao L, Jänne PA, Goto K, Rüttinger D, Descamps T, Brase JC, Bao W, Li R, Brega N, Grassi P, Girard N, Tan DS; SOHO-01 Investigators. Le X, et al. Among authors: ruttinger d. N Engl J Med. 2025 Nov 6;393(18):1819-1832. doi: 10.1056/NEJMoa2511065. Epub 2025 Oct 17. N Engl J Med. 2025. PMID: 41104928 Clinical Trial.
Anti-CSF-1R emactuzumab in combination with anti-PD-L1 atezolizumab in advanced solid tumor patients naïve or experienced for immune checkpoint blockade.
Gomez-Roca C, Cassier P, Zamarin D, Machiels JP, Perez Gracia JL, Stephen Hodi F, Taus A, Martinez Garcia M, Boni V, Eder JP, Hafez N, Sullivan R, Mcdermott D, Champiat S, Aspeslagh S, Terret C, Jegg AM, Jacob W, Cannarile MA, Ries C, Korski K, Michielin F, Christen R, Babitzki G, Watson C, Meneses-Lorente G, Weisser M, Rüttinger D, Delord JP, Marabelle A. Gomez-Roca C, et al. Among authors: ruttinger d. J Immunother Cancer. 2022 May;10(5):e004076. doi: 10.1136/jitc-2021-004076. J Immunother Cancer. 2022. PMID: 35577503 Free PMC article. Clinical Trial.
Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer.
Siegel F, Siegel S, Kotýnková K, Karsli Uzunbas G, Korr D, Tomono H, Andersen S, Denney D, Berger M, Schulze VK, Lewis TA, Kaplan B, Golfier S, Mortier J, Hillig RC, Boemer U, Petersen K, Eis K, Williams S, Rüttinger D, Cherniack AD, Loong HH, Goto K, Grassi P, Meyerson M, Greulich H. Siegel F, et al. Among authors: ruttinger d. Cancer Discov. 2025 Oct 15. doi: 10.1158/2159-8290.CD-25-0605. Online ahead of print. Cancer Discov. 2025. PMID: 41090369
Immunotherapy of lung cancer: an update.
Rüttinger D, Winter H, van den Engel NK, Hatz RA, Schlemmer M, Pohla H, Grützner S, Schendel DJ, Fox BA, Jauch KW. Rüttinger D, et al. Onkologie. 2006 Feb;29(1-2):33-8. doi: 10.1159/000090341. Onkologie. 2006. PMID: 16514254 Free article. Review.
Prognostic models: clinical impact now within reach.
Bauer-Mehren A, Rüttinger D. Bauer-Mehren A, et al. Among authors: ruttinger d. Ann Oncol. 2021 Jan;32(1):123-124. doi: 10.1016/j.annonc.2020.10.467. Epub 2020 Oct 17. Ann Oncol. 2021. PMID: 33080335 Free article. No abstract available.
Macrophage Susceptibility to Emactuzumab (RG7155) Treatment.
Pradel LP, Ooi CH, Romagnoli S, Cannarile MA, Sade H, Rüttinger D, Ries CH. Pradel LP, et al. Among authors: ruttinger d. Mol Cancer Ther. 2016 Dec;15(12):3077-3086. doi: 10.1158/1535-7163.MCT-16-0157. Epub 2016 Aug 31. Mol Cancer Ther. 2016. PMID: 27582524
69 results